scholarly journals REVIEW ON PANDEMIC OUTBREAK OF CORONAVIRUS (COVID-19): VIROLOGY, AVAILABLE TREATMENT, PREVENTION, AND FUTURE PROJECTION

2020 ◽  
pp. 1-6
Author(s):  
Abhijit Mohan Kanavaje ◽  
Vipul Ajit Sansare
Keyword(s):  
Early Stage ◽  
Scale Up ◽  
Therapeutic Agents ◽  
Family Welfare ◽  
The Novel ◽  
Future Projection ◽  
Potential Threat ◽  
Treatment Regimens ◽  
Treatment And Prevention ◽  
Novel Coronavirus

Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. On 11 March 2020, WHO declared Novel Coronavirus Disease (COVID-19) outbreak as a pandemic and reiterated the call for countries to take immediate actions and scale up the response to treat, detect and reduce transmission to save people’s lives. As of 3 April 2020, according to the Ministry of Health & Family Welfare (MoHFW), a total of 2301 COVID-19 cases (including 55 foreign nationals) have been reported in 29 states/union territories. These include 156 who have been cured/discharged,1 who has migrated, and 56 deaths in India. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines. The objective of this review article was to have a preliminary opinion about the disease, the ways of treatment, and prevention in this early stage of this outbreak.

scholarly journals Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0241543
Author(s):  
Sovesh Mohapatra ◽  
Prathul Nath ◽  
Manisha Chatterjee ◽  
Neeladrisingha Das ◽  
Deepjyoti Kalita ◽  
...  
Keyword(s):  
Machine Learning ◽  
Therapeutic Agents ◽  
The Novel ◽  
Epidemic Disease ◽  
Treatment Regimens ◽  
Antiretroviral Drug ◽  
Rapid Prediction ◽  
Bayes Algorithm ◽  
Novel Coronavirus ◽  
Smart Drug

Background The outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus has spread rapidly around the globe during the past 3 months. As the virus infected cases and mortality rate of this disease is increasing exponentially, scientists and researchers all over the world are relentlessly working to understand this new virus along with possible treatment regimens by discovering active therapeutic agents and vaccines. So, there is an urgent requirement of new and effective medications that can treat the disease caused by SARS-CoV-2. Methods and findings We perform the study of drugs that are already available in the market and being used for other diseases to accelerate clinical recovery, in other words repurposing of existing drugs. The vast complexity in drug design and protocols regarding clinical trials often prohibit developing various new drug combinations for this epidemic disease in a limited time. Recently, remarkable improvements in computational power coupled with advancements in Machine Learning (ML) technology have been utilized to revolutionize the drug development process. Consequently, a detailed study using ML for the repurposing of therapeutic agents is urgently required. Here, we report the ML model based on the Naive Bayes algorithm, which has an accuracy of around 73% to predict the drugs that could be used for the treatment of COVID-19. Our study predicts around ten FDA approved commercial drugs that can be used for repurposing. Among all, we found that 3 of the drugs fulfils the criterions well among which the antiretroviral drug Amprenavir (DrugBank ID–DB00701) would probably be the most effective drug based on the selected criterions. Conclusions Our study can help clinical scientists in being more selective in identifying and testing the therapeutic agents for COVID-19 treatment. The ML based approach for drug discovery as reported here can be a futuristic smart drug designing strategy for community applications.

scholarly journals The Impact of Armed Conflict on the Epidemiological Situation of COVID-19 in Libya, Syria and Yemen

2021 ◽  
Vol 9 ◽  
Author(s):  
Mohamed A. Daw
Keyword(s):  
Armed Conflict ◽  
Early Stage ◽  
Armed Conflicts ◽  
Cumulative Number ◽  
The Novel ◽  
Global Pandemic ◽  
Large Numbers ◽  
Public Data ◽  
Novel Coronavirus ◽  
The Impact

Background: Since the Arab uprising in 2011, Libya, Syria and Yemen have gone through major internal armed conflicts. This resulted in large numbers of deaths, injuries, and population displacements, with collapse of the healthcare systems. Furthermore, the situation was complicated by the emergence of COVID-19 as a global pandemic, which made the populations of these countries struggle under unusual conditions to deal with both the pandemic and the ongoing wars. This study aimed to determine the impact of the armed conflicts on the epidemiology of the novel coronavirus (SARS-CoV-2) within these war-torn countries and highlight the strategies needed to combat the spread of the pandemic and its consequences.Methods: Official and public data concerning the dynamics of the armed conflicts and the spread of SARS-COV-2 in Libya, Syria and Yemen were collected from all available sources, starting from the emergence of COVID-19 in each country until the end of December 2020. Datasets were analyzed by a set of statistical techniques and the weekly resolved data were used to probe the link between the intensity levels of the conflict and the prevalence of COVID-19.Results: The data indicated that there was an increase in the intensity of the violence at an early stage from March to August 2020, when it approximately doubled in the three countries, particularly in Libya. During that period, few cases of COVID-19 were reported, ranging from 5 to 53 cases/day. From September to December 2020, a significant decline in the intensity of the armed conflicts was accompanied by steep upsurges in the rate of COVID-19 cases, which reached up to 500 cases/day. The accumulative cases vary from one country to another during the armed conflict. The highest cumulative number of cases were reported in Libya, Syria and Yemen.Conclusions: Our analysis demonstrates that the armed conflict provided an opportunity for SARS-CoV-2 to spread. The early weeks of the pandemic coincided with the most intense period of the armed conflicts, and few cases were officially reported. This indicates undercounting and hidden spread during the early stage of the pandemic. The pandemic then spread dramatically as the armed conflict declined, reaching its greatest spread by December 2020. Full-blown transmission of the COVID-19 pandemic in these countries is expected. Therefore, urgent national and international strategies should be implemented to combat the pandemic and its consequences.

scholarly journals Consideration of the Management of Pediatric Fever Clinics During the Novel Coronavirus Pneumonia Outbreak

2020 ◽  
pp. 1-7
Author(s):  
Hui Ding ◽  
Zhaoling Shi ◽  
Zhen Ruan ◽  
Xiaoning Cheng ◽  
Ruying Li ◽  
...  
Keyword(s):  
Medical Staff ◽  
Prevention And Control ◽  
Cross Infection ◽  
The Novel ◽  
Wuhan City ◽  
Control Programs ◽  
Treatment And Prevention ◽  
Epidemic Period ◽  
Novel Coronavirus ◽  
And Control

ABSTRACT Since the outbreak of 2019 novel coronavirus (2019-nCoV) infection in Wuhan City, China, pediatric cases have gradually increased. It is very important to prevent cross-infection in pediatric fever clinics, to identify children with fever in pediatric fever clinics, and to strengthen the management of pediatric fever clinics. According to prevention and control programs, we propose the guidance on the management of pediatric fever clinics during the nCoV pneumonia epidemic period, which outlines in detail how to optimize processes, prevent cross-infection, provide health protection, and prevent disinfection of medical staff. The present consideration statement summarizes current strategies on the pre-diagnosis, triage, diagnosis, treatment, and prevention of 2019-nCoV infection, which provides practical suggestions on strengthening the management of pediatric fever clinics during the nCoV pneumonia epidemic period.

scholarly journals The basic reproduction number and prediction of the epidemic size of the novel coronavirus (COVID-19) in Shahroud, Iran

2020 ◽  
Vol 148 ◽  
Author(s):  
A. Khosravi ◽  
R. Chaman ◽  
M. Rohani-Rasaf ◽  
F. Zare ◽  
S. Mehravaran ◽  
...  
Keyword(s):  
Basic Reproduction Number ◽  
Reproduction Number ◽  
Early Stage ◽  
Screening Tests ◽  
The Novel ◽  
Epidemic Size ◽  
Serial Interval ◽  
Novel Coronavirus ◽  
Interval Distribution ◽  
The Basic Reproduction Number

Abstract The aim of this study was to estimate the basic reproduction number (R0) of COVID-19 in the early stage of the epidemic and predict the expected number of new cases in Shahroud in Northeastern Iran. The R0 of COVID-19 was estimated using the serial interval distribution and the number of incidence cases. The 30-day probable incidence and cumulative incidence were predicted using the assumption that daily incidence follows a Poisson distribution determined by daily infectiousness. Data analysis was done using ‘earlyR’ and ‘projections’ packages in R software. The maximum-likelihood value of R0 was 2.7 (95% confidence interval (CI): 2.1−3.4) for the COVID-19 epidemic in the early 14 days and decreased to 1.13 (95% CI 1.03–1.25) by the end of day 42. The expected average number of new cases in Shahroud was 9.0 ± 3.8 cases/day, which means an estimated total of 271 (95% CI: 178–383) new cases for the period between 02 April to 03 May 2020. By day 67 (27 April), the effective reproduction number (Rt), which had a descending trend and was around 1, reduced to 0.70. Based on the Rt for the last 21 days (days 46–67 of the epidemic), the prediction for 27 April to 26 May is a mean daily cases of 2.9 ± 2.0 with 87 (48–136) new cases. In order to maintain R below 1, we strongly recommend enforcing and continuing the current preventive measures, restricting travel and providing screening tests for a larger proportion of the population.

scholarly journals Abdominal symptoms as an initial manifestation of COVID-19 infection: Report of two cases

2020 ◽  
Author(s):  
PATRÍCIA YOKOO ◽  
Eduardo Kaiser Ururahy Nunes Fonseca ◽  
Marcelo Oranges Filho ◽  
Rodrigo Caruso Chate ◽  
Gilberto Szarf ◽  
...  
Keyword(s):  
Emergency Department ◽  
Respiratory Symptoms ◽  
Early Stage ◽  
The Novel ◽  
Initial Finding ◽  
Initial Manifestation ◽  
Abdominal Symptoms ◽  
Novel Coronavirus ◽  
Lung Base

Abstract The novel coronavirus (COVID-19) pandemic started in December 2019 in Wuhan (Hubei, China) and spread rapidly; therefore, it is essential to detect the disease at an early stage and immediately isolate the infected patients [1]. The most common symptoms of COVID-19 infection include fever, asthenia, cough and dyspnea [2]. However, some patients are asymptomatic from the respiratory symptoms, and may only present abdominal manifestations as an initial finding, what creates a diagnostic challenge.We describe two cases with diagnostic confirmations of COVID-19 who showed up at the Emergency Department with abdominal symptoms before presenting respiratory manifestations, and who had their initial suspicion based on the findings of the thoracoabdominal transition, demonstrating the importance of an adequate assessment of the lung base images.

scholarly journals Who Should Get Vaccinated First? An effective Network Information-driven Priority Vaccination Strategy

2021 ◽  
Author(s):  
Dong Liu ◽  
Chi Kong Tse ◽  
Rosa H. M. Chan ◽  
Choujun Zhan
Keyword(s):  
Large Scale ◽  
Early Stage ◽  
Vaccination Strategy ◽  
Cumulative Number ◽  
The Novel ◽  
Vaccination Programs ◽  
Network Information ◽  
Network Properties ◽  
Effective Network ◽  
Novel Coronavirus

Abstract Approval of emergency use of the Novel Coronavirus Disease 2019 (COVID-19) vaccines in many countries has brought hope to ending the COVID-19 pandemic sooner. Considering the limited vaccine supply in the early stage of COVID-19 vaccination programs in most countries, a highly relevant question to ask is: who should get vaccinated first? In this article we propose a network information- driven vaccination strategy where a small number of people in a network (population) are categorized, according to a few key network properties, into priority groups. Using a network-based SEIR model for simulating the pandemic progression, the network information-driven vaccination strategy is compared with a random vaccination strategy. Results for both large-scale synthesized networks and real social networks have demonstrated that the network information-driven vaccination strategy can significantly reduce the cumulative number of infected individuals and lead to a more rapid containment of the pandemic. The results provide insight for policymakers in designing an effective early-stage vaccination plan.

scholarly journals Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives

Nanomedicine ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. 497-516
Author(s):  
Hamid Rashidzadeh ◽  
Hossein Danafar ◽  
Hossein Rahimi ◽  
Faezeh Mozafari ◽  
Marziyeh Salehiabar ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Therapeutic Agents ◽  
Rapid Diagnosis ◽  
Socioeconomic Impact ◽  
The Novel ◽  
Future Perspectives ◽  
Mortality And Morbidity ◽  
Self Assembling ◽  
Novel Coronavirus ◽  
Significant Mortality

COVID-19, as an emerging infectious disease, has caused significant mortality and morbidity along with socioeconomic impact. No effective treatment or vaccine has been approved yet for this pandemic disease. Cutting-edge tools, especially nanotechnology, should be strongly considered to tackle this virus. This review aims to propose several strategies to design and fabricate effective diagnostic and therapeutic agents against COVID-19 by the aid of nanotechnology. Polymeric, inorganic self-assembling materials and peptide-based nanoparticles are promising tools for battling COVID-19 as well as its rapid diagnosis. This review summarizes all of the exciting advances nanomaterials are making toward COVID-19 prevention, diagnosis and therapy.

scholarly journals Immunopathogenesis of COVID-19 and early immunomodulators

2020 ◽  
Vol 63 (7) ◽  
pp. 239-250 ◽  
Author(s):  
Kyung-Yil Lee ◽  
Jung-Woo Rhim ◽  
Jin-Han Kang
Keyword(s):  
Lung Injury ◽  
Early Stage ◽  
Severe Pneumonia ◽  
Biochemical Properties ◽  
Etiologic Agent ◽  
Host Immune System ◽  
The Novel ◽  
Immune Mediated ◽  
Novel Coronavirus ◽  
Current Guidelines

The novel coronavirus disease 2019 (COVID-19) is spreading globally. Although its etiologic agent is discovered as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there are many unsolved issues in COVID-19 and other infectious diseases. The causes of different clinical phenotypes and incubation periods among individuals, species specificity, and cytokine storm with lymphopenia as well as the mechanism of damage to organ cells are unknown. It has been suggested that in viral pneumonia, virus itself is not a direct cause of acute lung injury; rather, aberrant immune reactions of the host to the insults from viral infection are responsible. According to its epidemiological and clinical characteristics, SARS-CoV-2 may be a virus with low virulence in nature that has adapted to the human species. Current immunological concepts have limited ability to explain such unsolved issues, and a presumed immunopathogenesis of COVID-19 is presented under the proteinhomeostasis-system hypothesis. Every disease, including COVID-19, has etiological substances controlled by the host immune system according to size and biochemical properties. Patients with severe pneumonia caused by SARS-CoV-2 show more severe hypercytokinemia with corresponding lymphocytopenia than patients with mild pneumonia; thus, early immunomodulator treatment, including corticosteroids, has been considered. However, current guidelines recommend their use only for patients with advanced pneumonia or acute respiratory distress syndrome. Since the immunopathogenesis of pneumonia may be the same for all patients regardless of age or severity and the critical immune-mediated lung injury may begin in the early stage of the disease, early immunomodulator treatment, including corticosteroids and intravenous immunoglobulin, can help reduce morbidity and possibly mortality rates of older patients with underlying conditions.

scholarly journals SARS – COV-2 (COVID-19) Pandemic: A Critical Review on Novel Coronavirus Pathogenesis, Clinical Diagnosis and Treatment

2020 ◽  
Vol 10 (3) ◽  
pp. 241-252
Author(s):  
Ruchi Jain ◽  
Nilesh Jain ◽  
Surendra Kumar Jain ◽  
Ram C Dhakar
Keyword(s):  
World Health ◽  
The Novel ◽  
Global Public Health ◽  
Future Studies ◽  
The Public ◽  
The Third ◽  
Treatment And Prevention ◽  
Published Evidence ◽  
Novel Coronavirus ◽  
Health Organization

The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19. The Novel coronavirus (SARS-CoV-2) caused pneumonia in Wuhan, China in December 2019 is a highly contagious disease. The World Health Organization (WHO) has declared it as a global public health emergency. This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002–2003 and MERS in 2012. Currently, the research on novel coronavirus is still in the primary stage. It is currently believed that this deadly Coronavirus strain originated from wild animals at the Huanan market in Wuhan by Bats, snakes and pangolins have been cited as potential carriers. On the basis of current published evidence, we systematically summarize the epidemiology, clinical characteristics, diagnosis, treatment and prevention of COVID-19. This review in the hope of helping the public effectively recognize and deal with the novel coronavirus (SARS-CoV-2) and providing a reference for future studies. Keywords: SARS-CoV-2, COVID-19, Coronavirus, pneumonia, Respiratory infection

scholarly journals Concept of emergence of a new coronavirus infection

2021 ◽  
Vol 17 (6) ◽  
pp. 547-551
Author(s):  
Valentina G. Dorofeychouck ◽  
Stella A. Sher
Keyword(s):  
The Body ◽  
The Novel ◽  
Review Of Literature ◽  
Protective Mechanisms ◽  
Functional Connection ◽  
Planetary Scale ◽  
Treatment And Prevention ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Genetically Determined

This report presents a brief review of literature and the authors’ concept of the emergence of the novel coronavirus 19 infection. The purpose of the work is to show the significance of lysozyme deficiency in the pathogenesis of COVID-19 based on data from literature sources and the results of the authors’ past studies. The relevance of the study is due to the planetary scale of the spread of coronavirus infection, the appearance of SARS-CoV-2 with new aggressive signs, the difficulties of their treatment and prevention. Anatomo-functional connection of protective mechanisms of lysozyme, mucopolysaccharides of histohaematic barriers with preservation of immune, biochemical and tissue homeostasis is established. The loss of lysozyme, which has genetically determined enzymatic specificity, contributes to the development of damaging processes of immune, biochemical and tissue nature with manifestation in all organs and systems of the body. Inclusion of exogenous lysozyme in basic therapy and prophylaxis COVID-19 is proposed.

Sign in / Sign up

Export Citation Format

Share Document